Defining Survivorship Trajectories Across Patients With Solid Tumors
- 1 November 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (11) , 1519-1526
Abstract
Importance Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities and secondary cancers, overseen by oncologists, surgeons, and primary care physicians. Optimal timing and coordination of care, however, is unclear and often based on arbitrary 5-year cutoffs. Objective To determine high- and low-risk periods for all tumor types that could define when survivorship care might best be overseen by oncologists and when to transition to primary care physicians. Design, Setting, and Participants In this pan-cancer, longitudinal, observational study, excess mortality hazard, calculated as an annualized mortality risk above a baseline population, was plotted over time. The time this hazard took to stabilize defined a high-risk period. The percent morality elevation above age- and sex-matched controls in the latter low-risk period was reported as a mortality gap. The US population–based Surveillance, Epidemiology, and End Results database defined the cancer population, and the US Census life tables defined controls. Incident cases of patients with cancer were separated into tumor types based onInternational Classification of Diseases for Oncologydefinitions. Exposures Population-level data on incident cancer cases was compared with the general US population. Main Outcomes and Measures Overall mortality and cause of death were reported on observed cancer cases. Results A total of 2 317 185 patients (median age, 63 years; 49.8% female) with 66 primary tumor types were evaluated. High-risk surveillance period durations ranged from less than 1 year (breast, prostate, lip, ocular, and parathyroid cancers) up to 19 years (unspecified gastrointestinal cancers). The annualized mortality gap, representing the excess mortality in the stable period, ranged from a median 0.26% to 9.33% excess annual mortality (thyroid and hypopharyngeal cancer populations, respectively). Cluster analysis produced 6 risk cluster groups: group 1, with median survival of 16.2 (5th to 95th percentile range [PR], 10.7-40.2) years and median high-risk period of 2.5 (PR, 0-5.0) years; group 2, 8.3 (PR, 5.1-23.3) and 2.5 (PR, 4.0-8.0) years; group 3, 2.8 (PR, 1.4-3.7) and 7.0 (PR, 6.0-11.1) years; group 4, 1.6 (PR, 1.5-1.8) and 6.0 (PR, 5.1-11.4) years; group 5, 0.8 (PR, 0.5-1.2) and 0.8 (PR, 0.5-1.2) years; and group 6, 0.5 (PR, 0.4-0.8) and 12.0 (PR, 9.3-12.9) years, respectively. Subanalyses of selected tumor types in these groups revealed that stratifying on stage and histologic type can change the risk cluster and guidance for care. Conclusions and Relevance These findings indicate that a standardized 5-year surveillance period is inadequate for some cancers while excessive for others. High-risk cancers require the most resources with the longest high-risk period, highest persistent baseline mortality risk, and longest period of primary cancer mortality, all arguing for longer follow-up with an oncologist in these cancers.Keywords
This publication has 12 references indexed in Scilit:
- Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)Gynecologic Oncology, 2017
- Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunitiesThe Lancet Oncology, 2017
- United States Life Tables, 2011.2015
- Cardio-Oncology: An Ongoing EvolutionFuture Oncology, 2015
- Models of Cancer Survivorship Care: Overview and Summary of Current EvidenceJournal of Oncology Practice, 2015
- Ward’s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward’s Criterion?Journal of Classification, 2014
- Cancer treatment and survivorship statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Risk-Based Health Care, the Cancer Survivor, the Oncologist, and the Primary Care PhysicianSeminars in Oncology, 2013
- Long-term Cause-Specific Mortality Among Survivors of Childhood CancerJAMA, 2010
- Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation ChemotherapyClinical Lung Cancer, 2009